ACTUS' strategy is to establish a subsidiary company for each licensed technology and to provide all of the financing, operational, research, development, and business partnering support the company requires during the initial stages of its development. In 2011, ACTUS established its first two subsidiary companies, Convoy Therapeutics, Inc. and EnduRx Pharmaceuticals, Inc., to develop and commercialize innovative platform technologies from University of California, Santa Barbara and the Sanford-Burnham Medical Research Institute. For further details, please visit our subsidiaries page.

ACTUS Biotechnologies is a technology development company, founded with the aim of identifying and providing a bridge to the commercialization of the most transformative technologies and drug candidates in development at leading universities and research institutes in the U.S. Run by a Management Team with significant experience in Life Sciences and in the growth and financing of start-up businesses, ACTUS is well positioned to maximize the potential of the inventions it licenses.

EnduRx Pharmaceuticals, Inc.

was founded in 2011 based on the multivalent tumor and cardiovascular homing nanotechnologies invented by Dr. Errki Ruoslahti and his laboratory at the Sanford-Burnham Medical Research Institute. The EnduRx nanotechnologies can selectively target, image, and treat cancerous tumors (glioblastoma, prostate, breast, and others), clotting events (myocardial infarction, stroke, peripheral artery disease, pulmonary embolism), and atherosclerosis. EnduRx Pharmaceuticals works with strategic partners on drugs that have targeting challenges from a safety and/or efficacy perspective, and on new cancer and cardiovascular diagnostic imaging applications. In-house programs include re-formulated Bivalirudin for Acute Coronary Syndrome and unique tumor targeting systems for glioblastoma, breast cancer, and solid tumors.

Convoy Therapeutics, Inc.

was founded in 2011 based on the proprietary Skin-Penetrating And Cell Entering (SPACE) peptide technology invented by Professor Samir Mitragotri and his laboratory at University of California, Santa Barbara. The SPACE peptide technology is the first that can effectively deliver large molecules into skin and cells. The delivery system has an optimal profile with skin penetration efficacy that far exceeds previous attempts. The SPACE peptide is neutral in charge, water soluble, and non-toxic to cells. It is used as part of a highly adaptable plug-and-play delivery system, whereby significant penetration into skin is possible without conjugation to the active. The company has two lead programs: CycloPsorbTM for psoriasis and HA-202PH (topical hyaluronic acid) for wrinkles and fine lines